ACCESS Newswire·Jun 16, 2026, 4:00 PM ET

Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics granted inducement awards to three newly hired employees on June 15, 2026.
The awards included options for 14,800 shares & RSUs for 3,900 shares of common stock.
The option exercise price was set at $112.46, matching the June 15, 2026 closing price on Nasdaq.
Options vest over four years with 25% vesting on the first anniversary & the remainder monthly thereafter.
RSUs vest one-fourth annually over a four-year period.
ICOTYDE launched in the U.S. in March 2026 for moderate-to-severe plaque psoriasis & is in Phase 3 for psoriatic arthritis, ulcerative colitis, & Crohn's disease.
The NDA for rusfertide to treat polycythemia vera is under priority FDA review.
The company continues development on programs including oral IL-17 antagonists, obesity agonists, & new IL-4 & amylin initiatives.